USAMRICD PROTECT, PROJECT, SUSTAIN MEDICAL MANAGEMENT OF CHEMICAL CASUALTIES NERVE AGENTS & PRETREAMENT U.S. ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL.

USAMRICDPROTECT, PROJECT, SUSTAIN

MEDICAL MANAGEMENT OF CHEMICAL CASUALTIESMEDICAL MANAGEMENT OF CHEMICAL CASUALTIES

NERVE AGENTS&

PRETREAMENT

U.S. ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE

NERVE AGENTS

USAMRICDPROJECT, PROTECT, SUSTAIN

NERVE AGENTS 2

DEFINITION

• A substance that causes biological effects by inhibiting acetylcholinesterase

• Acetylcholine accumulates

• Effects are due to excess acetylcholine

NERVE AGENTS


NERVE AGENTS 3

EXAMPLES• Carbamates

– Physostigmine (Antilirium)– Neostigmine (Prostigmine)– Pyridostigmine (Mestinon)– Sevin (insecticide)

• Organophosphates– Malathion– Diazinon– “Nerve Agents”

NERVE AGENTS


NERVE AGENTS 4

NERVE AGENTS

• GA (Tabun)

• GB (Sarin)

• GD (Soman)

• GF

• VX

NERVE AGENTS


NERVE AGENTS 5

GA

CH3 CH2 O

O

P

CH3

CH3

N

CN

NERVE AGENTS


NERVE AGENTS 6

GB

CH3

O

OP

CH3

CH3F

CH

NERVE AGENTS


NERVE AGENTS 7

GD

CH3

O

OP

CH3

CH3F

CH C

CH3

CH3

NERVE AGENTS


NERVE AGENTS 8

VX

CH3O

SP CH2N

CH(CH3)2

CH2

CH3CH2O

CH(CH3)2

NERVE AGENTS


NERVE AGENTS 9

HISTORY

• Germany, WW II, nerve agent munitions

• Used by Iraq

• In stockpiles

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 10

TERRORIST USE

• Matsumoto, 1994

– 7 deaths

• Tokyo, 1995

– 12 deaths

NERVE AGENTS


NERVE AGENTS 11

PHYSICAL PROPERTIES

• Clear, colorless liquids (when fresh), not “nerve gas”

• Tasteless, most are odorless

• Freeze/melt <0º C

• Boil >150º C

• Volatility GB>GD>GA>GF>VX

• Penetrate skin, clothing

NERVE AGENTS


NERVE AGENTS 12

TOXICITY

LCt50 LD50

mg-min/m3 mg/70kg

GA 400 1,000

GB 100 1,700

GD 70 50

GF 50 30

VX 10 10

NERVE AGENTS


NERVE AGENTS 13

CHOLINESTERASE

• Blood

– Acetyl (red cell, erythrocyte, “true”)

– Butyryl (plasma, pseudo)

• Tissue

– Tissue acetylcholinesterase (at cholinergic receptor sites)

NERVE AGENTS


NERVE AGENTS 14

EXPOSURE INDICATORS

• Inhibition of

• Acetylcholinesterase (RBC)

– most sensitive for nerve agent

• Butyrylcholinesterase (plasma)

– more sensitive for most insecticides

NERVE AGENTS


NERVE AGENTS 15

PHYSIOLOGY: NORMAL• Electrical impulse goes down nerve

• Impulse causes release of neurotransmitter, acetylcholine

• ACh stimulates receptor site on organ

• Causes organ to act

• ACh is destroyed by AChE

• No more organ activity

NERVE AGENTS


NERVE AGENTS 16

Nerve Transmission: Nerve to Nerve

ACh

NERVE AGENTS


NERVE AGENTS 17


ACh

NERVE AGENTS


NERVE AGENTS 18


ACh

NERVE AGENTS


NERVE AGENTS 19

Nerve Transmission: Nerve to Skeletal Muscle

NERVE AGENTS


NERVE AGENTS 20

Nerve Transmission: Nerve to Smooth Muscle

NERVE AGENTS


NERVE AGENTS 21

Nerve Transmission: Nerve to Exocrine Gland

NERVE AGENTS


NERVE AGENTS 22

Impulse Termination: The Role of AChE

ACh

AChE

NERVE AGENTS


NERVE AGENTS 23

Impulse Termination: The Role of AChE

ACh

AChE

NERVE AGENTS


NERVE AGENTS 24

PHYSIOLOGY: NERVE AGENT

• Enzyme (AChE) is inhibited

• Does not destroy ACh

• Excess ACh continues to stimulate organ

• Organ overstimulation

NERVE AGENTS


NERVE AGENTS 25

Exposure to Nerve Agent

ACh

AChE

NERVE AGENTS


NERVE AGENTS 26

Exposure to Nerve Agent

ACh

AChE

NERVE AGENTS


NERVE AGENTS 27

Effects on Striated (Skeletal) Muscle

ACh

AChE

NERVE AGENTS


NERVE AGENTS 28

Effects on Smooth and Cardiac Muscle

ACh

AChE

NERVE AGENTS


NERVE AGENTS 29

Effects on Exocrine Glands

ACh

AChE

NERVE AGENTS


NERVE AGENTS 30

ORGANS

• Muscarinic– Smooth muscles– Exocrine glands– Cranial nerves (vagus)

• Nicotinic– Skeletal muscles– Pre-ganglionic nerves

• Both– CNS

NERVE AGENTS


NERVE AGENTS 31

EFFECTS

• Muscarinic– Smooth muscles

• Airways - constrict

• GI tract - constrict

• Pupils - constrict

– Glands• Eyes, nose, mouth, sweat, airways, GI

– Heart, bradycardia (vagal)

NERVE AGENTS


NERVE AGENTS 32

NICOTINIC

• Skeletal muscles

– Fasciculations, twitching, fatigue, flaccid

paralysis

• Pre-ganglionic

– Tachycardia, hypertension

NERVE AGENTS


NERVE AGENTS 33

ACh at Receptors

ACh

ACh ACh

ACh

Nicotinic Nicotinic

Muscarinic Muscarinic

Preganglionicsynapses in ANS

Skeletal muscle

Synapses in CNS

Smooth muscle

Exocrine glands

NERVE AGENTS


NERVE AGENTS 34

HEART RATE

• Muscarinic (vagal) decreases

• Nicotinic (ganglionic) increases

• May be high, low, normal

NERVE AGENTS


NERVE AGENTS 35

CNS

• Acutely, large exposure

– Loss of consciousness

– Seizures

– Apnea

– Death

NERVE AGENTS


NERVE AGENTS 36

CNS

• Acutely, small exposure– Minor CNS effects

• Slowness in thinking and decision making• Sleep disturbances• Poor concentration• Emotional problems• Other minor problems

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 37

CNS

• Minor CNS effects

– May last for 3 to 6 weeks

– May follow any exposure

– Not always present

– Very slight, subtle

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 38

VAPOR

• Small exposure– Eyes: Miosis; injection; dim,

blurred vision; pain; maybe nausea, vomiting

– Nose: Rhinorrhea

– Mouth: Salivation

– Airways: Shortness of breath

NERVE AGENTS


NERVE AGENTS 39

VAPOR - NOSE and MOUTH

• Runny nose

– Worse than cold or hay fever

– Leaking faucet

• Mouth

– Excessive saliva

– May run out corners

NERVE AGENTS


NERVE AGENTS 40

VAPOR - RESPIRATORY TRACT

• Small exposure– Tight chest

• Moderate exposure– Severe breathing

difficulty

– Gasping, irregular breathing

– Compounded by excessive secretions

NERVE AGENTS


NERVE AGENTS 41

VAPOR - GASTROINTESTINAL

• Exposure to a large but not lethal concentration may cause:

– Nausea, vomiting

– Pain in abdomen

– Diarrhea, involuntary defecation or urination

NERVE AGENTS


NERVE AGENTS 42

VAPOR - CARDIAC

• Heart rate

– Increase or decrease

– Blood pressure - increase

– Not an indicator for care

NERVE AGENTS


NERVE AGENTS 43

VAPOR

• Onset of effects: seconds to minutes

• After removal from vapor

– Effects do not worsen

– May improve

• No late-onset effects

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 44

VAPOR

• Large exposure

• Previously listed effects plus...– Loss of consciousness

– Seizures

– Apnea

– Flaccid paralysis

– Death

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 45

LIQUID ON SKIN• Small droplet: local effects

– Sweating, fasciculations

• Medium droplet: systemic effects

– GI

• Large droplet: CNS

– Loss of consciousness, seizures, apnea, flaccid paralysis, death

NERVE AGENTS


NERVE AGENTS 46

LIQUID ON SKIN

• Onset of effects

– Small, medium drop

• As long as 18 hours

– Large, lethal drop

• Usually <30 minutes

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 47

LIQUID ON SKIN

• Onset time, penetration

– Skin site

– Temperature

– Moisture

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 48

LIQUID ON SKIN

• Effects may occur despite initial

decontamination

• Effects may worsen

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 49

MIOSIS

• Almost always after vapor

• After liquid on skin:

– Small: no

– Moderate: maybe

– Severe: yes

NERVE AGENTS


NERVE AGENTS 50

MANAGEMENT

• ABCs

• Drugs

• Decontamination

• Supportive

• Not necessarily in that order

NERVE AGENTS


NERVE AGENTS 51

MANAGEMENT

• MOST IMPORTANT

• Protect self

– Protective gear

– Decontaminate casualty

• Protect medical facility

– Decontaminate casualty

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 52

DETECTION

• M256A1

• Chemical Agent Monitor

• M8 and M9 paper

• M8A1Automatic Chemical Agent Alarm

NERVE AGENTS


NERVE AGENTS 53

PROTECTIVE POSTURE

MOPP 4!!!!!!

NERVE AGENTS


NERVE AGENTS 54

SKIN DECONTAMINATION

• Early is best, within 1 to 2 minutes– Little benefit after 30 minutes

• Physical removal is best– Forceful flush with water– Stick, dirt, cloth, M291

• Solutions (hypochlorite, etc.)– Detoxify after many minutes

NERVE AGENTS


NERVE AGENTS 55

VENTILATION

• Possibly less need after pyridostigmine

• None forward of Battalion Aid Station

• Very high airway resistance until atropine is given

NERVE AGENTS


NERVE AGENTS 56

ANTIDOTES

• Too much acetylcholine

– Block excess acetylcholine

• Enzyme inhibited

– Reactivate enzyme

NERVE AGENTS


NERVE AGENTS 57

ATROPINE

• A cholinergic blocking drug– An anticholinergic

• Blocks excess acetylcholine

• Clinical effects at muscarinic sites– Dries secretions

– Reduces smooth muscle constriction

NERVE AGENTS


NERVE AGENTS 58

Atropine at Receptors

NicotinicNicotinic

Muscarinic Muscarinic

Atropine

AtropineAtropine

Atropine

NERVE AGENTS


NERVE AGENTS 59

ACh and Atropine at Receptors

ACh

ACh

ACh

Nicotinic

Muscarinic

Atropine

Nicotinic

Muscarinic

Atropine

NERVE AGENTS


NERVE AGENTS 60

ATROPINE• Side effects in unexposed• Starting dose 2 mg or 6 mg• More, 2 mg every 5 to 10 minutes• Until

– Secretions drying– Ventilation improved

• Usual dose: (severe casualty) 15 to 20 mg– 1000s of mgs in insecticide

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 61

ATROPINE

• Not for

– Skeletal muscle effects

– Miosis, unless used topically

• Use will cause blurred vision for 24 hours

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 62

Action of Atropine on Smooth Muscle

ACh

AChE

AtrAtr

AtrAtr

Atr

Atr

Atr

Atr

Atr

Atr

Atr

Atr

AtrAtr

Atr

Atr

Atr

Atr

Atr

NERVE AGENTS


NERVE AGENTS 63

Effects on Exocrine Glands

ACh

AChE

AtrAtrAtr

Atr

Atr

AtrAtr

Atr

Atr

AtrAtr

AtrAtr

Atr

NERVE AGENTS


NERVE AGENTS 64

Effects on Striated (Skeletal) Muscle: None!

ACh

AChE

Atr

Atr

Atr

Atr

Atr

Atr

Atr

Atr

NERVE AGENTS


NERVE AGENTS 65

OXIMES

• Effects at nicotinic sites

– Increase skeletal muscle strength

• No clinical effects at muscarinic sites

NERVE AGENTS


NERVE AGENTS 66

Action of Pralidoxime Chloride (2-PAM Cl)

AChE NerveAgent

2-PAM Cl

NERVE AGENTS


NERVE AGENTS 67

ACTION OF PRALIDOXIME CHLORIDE(2-PAM Cl)

AChE

2-PAM Cl

Nerve Agent

NERVE AGENTS


NERVE AGENTS 68

OXIMES

• Remove agent from enzyme, unless aging has occurred

• Aging: agent-enzyme complex changes

• Oximes cannot reactivate enzyme

• Aging times: GD 2 min

GB 3 to 4 hours

Others longer

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 69

Aging of the Nerve Agent-AChE Complex

AChE NerveAgent

NERVE AGENTS


NERVE AGENTS 70

Introduction of 2-PAM Cl after Aging

NERVE AGENTS


NERVE AGENTS 71

OXIMES

• Other countries have different ones

– England: P2S

– Some European countries: obidoxime

– Israel: TMB4

– Japan: 2-PAMI

CONTINUEDCONTINUED

NERVE AGENTS


NERVE AGENTS 72

2-PAMCL DOSE

• NAAK (MARK I): contains 600 mg

– One or three Combopens; repeat in one hour

• IV: One gram slowly (20 to 30 min)

– Repeat in one hour

NERVE AGENTS


NERVE AGENTS 73

SEIZURES• Without pyridostigmine

– Not prolonged – Anticonvulsant seldom necessary

• Prolonged after pyridostigmine– Possible brain damage from prolonged

seizures– Anticonvulsant needed (diazepam)

• Give diazepam to any severe casualty

NERVE AGENTS


NERVE AGENTS 74

ARRHYTHMIAS

• Initial, transient from agent, atropine

• Terminal after hypoxia

• V-fib if atropine given IV with hypoxia

NERVE AGENTS


NERVE AGENTS 75

RECOVERY

• Severe casualty:

– Without complications, conscious, breathing, in 2 to 3 hours

NERVE AGENTS


NERVE AGENTS 76

RETURN TO DUTY

• Dose-dependent, need dependent

• Could be hours with minor exposure, great need

• Many days after severe exposure

• Consider:– Vision– Minor, subtle mental effects

NERVE AGENTS


NERVE AGENTS 77

LONG TERM

• EEG changes not detected in individuals

– Minor changes detected in an averaged group

– Significance unknown

NERVE AGENTS


NERVE AGENTS 78

MARK I

• Spring powered injectors

– Atropine, 2 mg/0.7 ml

– 2-PAMCl, 600 mg/2 ml

NERVE AGENTS


NERVE AGENTS 79

MARK I AUTO-INJECTOR

NERVE AGENTS


NERVE AGENTS 80

MILD VAPOR EXPOSURE

• Miosis, rhinorrhea

• Rx: Probably none unless rhinorrhea is

severe

• Atropine IM will not help miosis

NERVE AGENTS


NERVE AGENTS 81

MODERATE VAPOR EXPOSURE

• Miosis, rhinorrhea, moderate or severe dyspnea

• Walking and talking

• Rx: 1 MARK I(if dyspnea is quite severe: 2 MARK Is)

NERVE AGENTS


NERVE AGENTS 82

SEVERE VAPOR EXPOSURE

• Conscious or unconscious

• Seizing or post-ictal

• Breathing or not

• Or effects in two or more systems(airway, GI, muscular, CNS)

NERVE AGENTS


NERVE AGENTS 83

SEVERE VAPOR EXPOSURE

• Rx: 3 MARK Is and diazepam ASAP

• Ventilation

• Rx even after cardiac arrest

NERVE AGENTS


NERVE AGENTS 84

MILD LIQUID EXPOSURE

• Localized twitching, sweating

• Rx: 1 MARK I (agent has been absorbed)

NERVE AGENTS


NERVE AGENTS 85

MODERATE SKIN EXPOSURE

• GI effects: vomiting, diarrhea, cramps

• Rx: 1 MARK I

• Watch carefully for 18 hours

NERVE AGENTS


NERVE AGENTS 86

SEVERE SKIN EXPOSURE

• Conscious or unconscious

• Seizing or post-ictal

• Breathing or not

• Or effects in two or more systems(airway, GI, muscular, CNS)

NERVE AGENTS


NERVE AGENTS 87

SEVERE SKIN EXPOSURE

• Rx: 3 MARK Is and diazepam

• Ventilation

• Rx after cardiac arrest



NERVE AGENTSA Case Study From the Tokyo

Subway Incident


NERVE AGENTS


NERVE AGENTS 89

Tokyo Subway Victim• 35-year-old man• Exposed to sarin during the Tokyo subway attack 20

MAR 95• For approximately 7 minutes after exposure:

– Had tonic-clonic convulsions– Episodes of dyspnea, during which he needed artificial

respiration

• In the hospital emergency room he was comatose and mildly cyanosed

• Both pupils were constricted to 1.5 mm• Had increased oral and nasal secretions and profuse

sweating and vomiting

NERVE AGENTS


NERVE AGENTS 90

Tokyo Subway Victim

• Atropine sulphate and pralidoxime iodide were given intravenously

• The patient began to regain consciousness 8 hours after exposure

• Regained full mobility after 54 hours

• He was, however, disoriented and had an impaired short-term memory

• His electroencephalogram showed mild slowing of alpha activity, intermittent theta bursts, and the development of

delta busts during hyperventilation

– disappeared 3 months after exposure

• CT and MRI imaging showed no focal lesions

• Plasma cholinesterase activity, which was markedly low at 6% of normal levels after exposure, was normal within 3

weeks

• RBC cholinesterase activity was normal after 3 months

NERVE AGENTS


NERVE AGENTS 91

Tokyo Subway Victim• Neuropsychological tests 6 months after exposure showed no global intellectual

impairment or defects in immediate recall

• All his errors on the Mini Mental State were related to recall and temporal orientation

• Performance was particularly impaired on the Logical Memory and Associate Learning scales from the Wechsler Memory Scale-Revised

• Ability to copy the Rey-Osterrieth complex figure was normal (36/36)

• However, when he was asked to reproduce the drawing 3 and 30 minutes later, his performance was worse (18/36 and 3/36, respectively)

• These results suggest a defect in his ability to consolidate new learning and memory

• Furthermore, without confabulation, he showed retrograde amnesia that extended to 70 days before exposure to sarin

• Personality changes characterized by passivity and shallow affect were also evident

NERVE AGENTS


NERVE AGENTS 92

Tokyo Subway Victim• The extent and consequences of brain injury and incapacity due to

nerve gas poisoning in human beings are not understood

• Patient had amnesia similar to that caused by severe acute hypoxia

• Hypoxia may have been a factor in our patient during the first 7 minutes after exposure

• Defects such as retrograde amnesia and character changes might be associated with the direct effects of excess choline

Hatta K et al., Lancet 347:1343, 1996


PRETREATMENT FOR NERVE AGENT POISONING


NERVE AGENTS


NERVE AGENTS 94

TERMINAL OBJECTIVE

• Apply principles of pyridostigmine use in enhancing drug therapy for nerve agent intoxication

NERVE AGENTS


NERVE AGENTS 95

WHY?

• Major threat agent: Soman

• Therapy for soman: relatively ineffective

NERVE AGENTS


NERVE AGENTS 96

CARBAMATES

• Transient carbamylation of AChE

• Protects site from OP (nerve agent)

• Carbamylation of only small amount of AChE needed

NERVE AGENTS


NERVE AGENTS 97

Action of Pyridostigmine

Pyridostigmine

AChE

NERVE AGENTS


NERVE AGENTS 98


AChEPyridostigmine

NERVE AGENTS


NERVE AGENTS 99


AChEPyridostigmine

NerveAgent

NERVE AGENTS


NERVE AGENTS 100


AChEPyridostigmine

NERVE AGENTS


NERVE AGENTS 101

Pretreatment

• Pretreatment alone, without therapy provides no benefit

• Pretreatment followed by antidotes after nerve agent: beneficial

NERVE AGENTS


NERVE AGENTS 102

Protective Ratio

• PR =

• PR of 1.0: No effect

• PR of 5.0 desirable for the battlefield

• PR of antidotes against GD: 1.6

LD50 (treated)

LD50 (untreated)

NERVE AGENTS


NERVE AGENTS 103

PR Study in Rhesus Monkeys

GroupGroup LD50 of GDLD50 of GD PRPR

ControlControl 15.3 mcg/kg15.3 mcg/kg 1.0 1.0

Mark I onlyMark I only 25.1 mcg/kg25.1 mcg/kg 1.6 1.6

NAPP + Mark I NAPP + Mark I > 617 mcg/kg> 617 mcg/kg > 40 > 40

NERVE AGENTS


NERVE AGENTS 104

UTILITY OF PRETREATMEN T

• Helpful against: GD, GA

• No added benefit: GB, GF, VX

NERVE AGENTS


NERVE AGENTS 105

BEFORE USE

• Efficacy

• Safety– Short-term

• Side Effects• Performance

– Long-term

NERVE AGENTS


NERVE AGENTS 106

SHORT TERM

• Side effects: <5% of those taking it

• Performance: No decrements in military tasks (including shooting, flying, driving, physical tasks)

NERVE AGENTS


NERVE AGENTS 107

LONG TERM

• Animal studies

• Myasthenia gravis patients – Starting dose usually 60 mg q8h, can go

much higher– Usual course of treatment is years, not weeks

NERVE AGENTS


NERVE AGENTS 108

DOSE REGIMEN

• Dose: 30 mg– Based on RBC-ChE– Inhibition

• Interval: 8 hours– Based on pharmacokinetics of pyridostigmine

• Dosing: 30 mg every 8 hours

• Commander starts, stops use

NERVE AGENTS


NERVE AGENTS 109

WHAT DO YOU SAY IF YOUR COMMANDER ASKS:

• How long after I order pyridostigmine do I have to wait until my troops are protected?

• How soon after I order them to stop taking it can I consider them at risk?

NERVE AGENTS


NERVE AGENTS 110

PYRIDOSTIGMINE: USE

• Mestinon : five decades for myasthenia gravis

• Regonal : anesthesia

NERVE AGENTS


NERVE AGENTS 111

PYRIDOSTIGMINE

• Insignificant binding to plasma proteins

• Bioavailability after oral dose: 8 to 29%

• Elimination: <75% in urine

• Maximal plasma concentration: 1.5 to 2.0 hours

• Elimination half time: 3.5 hours

NERVE AGENTS


NERVE AGENTS 112

PYRIDOSTIGMINE: USE IN GULF WAR

• Compliance unknown

• High incidence (>50%) of side effects

• Most related to pharmacology of drug– GI >50%– GU 5 to 30%

• Medical assistance 1%

• Discontinuance drug <0.1%

NERVE AGENTS


NERVE AGENTS 113

Israeli Study

• Effects of Pyridostigmine on troops in field conditions

– Done under FTX conditions at basic training on 80 troops

– Half of them given pyridostigmine 30 mg q8h or placebo

– Studied before and after 8-day period on drug or placebo

– Study design is double blinded but not crossover

NERVE AGENTS


NERVE AGENTS 114

Results of the Israeli study

• Pyridostigmine-treated soldiers had “mild” GI symptoms in most cases

• Pyridostigmine-treated soldiers had changes on order of 10% in their scores on vertical addition and four-choice (perceptual speed) tasks.

– Other neuropsychiatric parameters were unaffected.

• The two groups had no difference in their endocrine or stress tests including cortisol

NERVE AGENTS


NERVE AGENTS 115

Conclusions:

• Soldiers did as well functionally with as without pyridostigmine

• Functional significance of neuropsychiatric changes is unclear• Commanders and their troops had no complaints and those

with mild changes were functionally unaware of them.

Limitation:No systematic long-term follow-up

–MAJ Givoni Israeli Defence Force

NERVE AGENTS


NERVE AGENTS 116

PYRIDOSTIGMINE

• After pretreatment, nerve agent, antidotes: breathing and seizures continue

• Potential brain damage

• Anticonvulsant (diazepam) needed (10 mg via auto-injector)

NERVE AGENTS


NERVE AGENTS 117

Effects of Long-term Administration

• In vitro and in vivo evidence of myopathy

• Complaints of weakness, fatigue, etc.

• U.K. 60-day study

• U.S. doctrine does not advocate long-term use

NERVE AGENTS


NERVE AGENTS 118

PYRIDOSTIGMINE: SUMMARY

• Pretreatment, not a substitute for treatment

• “Hides” or protects a fraction of AChE (creates a “reserve force”

• Increases the amount of nerve agent a person can be exposed to and survive

• Causes predictable side effect profile

• Does not interfere with military function


SUMMARYANY QUESTIONS?



USAMRICD PROTECT, PROJECT, SUSTAIN MEDICAL MANAGEMENT OF CHEMICAL CASUALTIES NERVE AGENTS & PRETREAMENT U.S. ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL.

Documents

nerve agents usamricd

nerve transmission

nerve agent munitions

clothing slide

o o p f ch slide

excess acetylcholine

organ activity slide

n cn slide